openPR Logo
Press release

U.S Bacterial Conjunctivitis Drugs Market to Reach USD 439.8 Million in 2024

U.S Bacterial Conjunctivitis Drugs Market to Reach USD 439.8

According to a new market report published by Persistence Market Research “The U.S Market Study on Bacterial Conjunctivitis Drugs: fluoroquinolones to be the Largest Segment by 2024” the bacterial conjunctivitis drugs market in the U.S. was valued at USD 473.3 million in 2013 and is estimated to reach a market worth of USD 439.8 million in 2024, at a CAGR of2.7%from 2012 to 2018 and (-3.73%) from 2018 to 2024.

Conjunctivitis is an inflammation of the conjunctiva - the clear membrane that covers the outermost layer of an eye and the inner surface of eyelids. Conjunctivitis is segmented into three major categories: infective (viral and bacterial), allergic, and irritant (chemical). Bacterial conjunctivitis is one of the most commonly observed eye problems across all age groups, generally caused by bacteria such as Staphylococcus aureus, Moraxella lacunata, Haemophilus influenza, and others (e.g. Chlamydia trachomatis, Proteus mirabilis, etc.). As reported by Healio (specialty medical news and journal publisher), approximately 5 million acute bacterial conjunctivitis cases are reported in the U.S. each year. Thus, high prevalence of bacterial conjunctivitis in the country demands effective medications, thereby driving the growth of the bacterial conjunctivitis drugs market in the U.S.However, despite the increasing incidence of bacterial conjunctivitis, the overall bacterial conjunctivitis market in the U.S. is likely to witness negative growth due to the patent expirations of major blockbuster drugs such as Vigamox, Moxeza, Zymaxid, and Besivance in the next few years.

Request to Sample Report @ https://www.persistencemarketresearch.com/samples/5192

Rise in ophthalmic bacterial infections is increasing the demand for antibacterial drugs in the U.S. According to a clinical study conducted by the scientists Amir A. Azari and Neal P. Barney, published in the Journal of the American Medical Association (JAMA) in 2013, bacterial conjunctivitis accounts for over 50% of the conjunctivitis cases in the U.S. It also quoted that the incidence of bacterial conjunctivitis was estimated to be 135 in 10,000 in a single study.These statistics indicate that the U.S. is witnessing high incidence of bacterial conjunctivitis, hence leading to increased demand for bacterial conjunctivitis drugs in the country.

Fluoroquinolones, aminoglycosides, macrolides and other antibacterials such as bacitracin, doxycycline, and ceftriaxone collectively form the bacterial conjunctivitis market; among which fluoroquinolones dominate the bacterial conjunctivitis drugs market in the U.S. with a share of more than 70% in 2013. Fluoroquinolones are more widely prescribed as compared to other antibiotic drug classes for the treatment of bacterial conjunctivitis across the U.S. due to their higher efficacy against antibiotic-resistant bacterial strains and broad spectrum activity. However, the segment is expected to witness a significant decline in sales in the near future -from a CAGR of 4.9% from 2012 to 2018 to a CAGR of (-8.1%) from 2018 to 2024. Burgeoning influx of generic antibacterials as well as upcoming patent expiries of leading branded formulations such as Vigamox, Zymaxid, Moxeza, and Besivance are a few major factors that would adversely affect the growth of the segment.

With the loss of patent exclusivity, generics would offer physicians a broad range of affordable medications to prescribe, thereby significantly reducing the overall size of the bacterial conjunctivitis drugs market in the U.S. Hence, the future market growth would be contingent on commercialization of novel drugs for new indications. However, it has been observed that although the incidence rate of bacterial conjunctivitis is moderate in the U.S., the risk of morbidity is less, due to which the novel product pipeline for bacterial conjunctivitis is weak/dry. At present, only a few novel compounds are under investigation in both preclinical and clinical settings for the treatment of bacterial conjunctivitis.

Request Report TOC @ https://www.persistencemarketresearch.com/methodology/5192

The U.S. bacterial conjunctivitis drugs market displays intense competitive rivalry among existing players, as currently the market is highly fragmented comprising both large and small pharmaceutical companies. Key players profiled in this study include organizations such as Actavis plc, Akorn, Inc., Bayer AG, F. Hoffmann-La Roche, Ltd., Merck & Co., Inc., Novartis AG, Perrigo Company plc, Pfizer, Inc., Santen Pharmaceutical Co., Ltd., and Valeant Pharmaceuticals International, Inc.

ABOUT US:
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

CONTACT:
Persistence Market Research
305 Broadway,7th Floor
New York City, NY 10007
United States
T: +1-646-568-7751
Tollfree: +1 800-961-0353

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release U.S Bacterial Conjunctivitis Drugs Market to Reach USD 439.8 Million in 2024 here

News-ID: 1450091 • Views:

More Releases from Persistence Market Research

North America Wiring Devices Market Projected to Reach USD 26.46 Billion by 2031
North America Wiring Devices Market Projected to Reach USD 26.46 Billion by 2031
Overview of the North America Wiring Devices Market The North America wiring devices market is poised for steady growth over the forecast period, with its size estimated at US$ 18.96 billion in 2024, projected to reach US$ 26.46 billion by 2031, reflecting a CAGR of 4.9%. The market is witnessing substantial expansion due to increasing urbanization, a rising number of residential and commercial construction projects, and the adoption of energy-efficient and
Global Forged Automotive Components Market Poised for Steady Growth, Projected to Reach US$ 70.7 Billion by 2032
Global Forged Automotive Components Market Poised for Steady Growth, Projected t …
The global forged automotive components market is on a robust growth trajectory, currently valued at approximately US$ 50.3 billion in 2025 and forecasted to expand to US$ 70.7 billion by the end of 2032. This growth represents a compound annual growth rate (CAGR) of 5.0% over the coming decade, driven by increasing automotive production, technological advancements, and evolving consumer preferences toward durable, high-performance vehicle parts. Forged automotive components are critical to
Global Electric Cargo Bike Market Set to Accelerate at 11.9% CAGR, Reaching US$ 2.14 Billion by 2032, Reports Persistence Market Research
Global Electric Cargo Bike Market Set to Accelerate at 11.9% CAGR, Reaching US$ …
The global electric cargo bike market is set to experience substantial growth over the coming decade, with Persistence Market Research (PMR) forecasting a compound annual growth rate (CAGR) of 11.9% from 2023 through 2032. Valued at approximately US$ 800 million in 2021, the market is expected to surge to a projected valuation of US$ 2.14 billion by the end of 2032. Notably, electric cargo bikes accounted for 66.2% of the
Bicycle Bearings Market Set for Steady Growth with 6.5% CAGR Through 2032, Driven by Urbanization and Demographic Trends
Bicycle Bearings Market Set for Steady Growth with 6.5% CAGR Through 2032, Drive …
The global bicycle bearings market is poised for significant expansion over the forecast period of 2025 to 2032, according to the latest report released by Persistence Market Research. Valued at approximately US$ 5.99 billion in 2024, the market is projected to reach US$ 6.35 billion by 2025 and further escalate to nearly US$ 9.86 billion by 2032. This growth trajectory reflects a compound annual growth rate (CAGR) of 6.5%, underscoring

All 5 Releases


More Releases for Conjunctivitis

Rising Prevalence Of Conjunctivitis Propelling Growth In The Conjunctivitis Trea …
The Conjunctivitis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Projected Growth of the Conjunctivitis Treatment Market? The Conjunctivitis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores
Prominent Bacterial Conjunctivitis Market Trend for 2025: Innovative Eye Drops T …
What Are the Projected Growth and Market Size Trends for the Bacterial Conjunctivitis Market? The bacterial conjunctivitis market has grown steadily, projected to expand from $4.52 billion in 2024 to $4.76 billion in 2025, at a CAGR of 5.3%. Growth factors include rising bacterial infection cases, improved diagnostics, patient education programs, stringent regulatory frameworks, and physician training. The bacterial conjunctivitis market is projected to grow steadily, reaching $5.54 billion by 2029 at
Allergic Conjunctivitis Market - Clear Eyes, Allergy-Free: Allergic Conjunctivit …
Newark, New Castle, USA: The "Allergic Conjunctivitis Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Allergic Conjunctivitis Market: https://www.growthplusreports.com/report/allergic-conjunctivitis-market/7892 This latest report researches the industry structure, sales, revenue,
Allergic Conjunctivitis Market - Empowering Eyes, Enhancing Lives: Redefining Al …
Newark, New Castle, USA - new report, titled Allergic Conjunctivitis Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Allergic Conjunctivitis market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Allergic Conjunctivitis market. The report offers an overview of the market, which
Conjunctivitis Market - key players covered:Pfizer, Inc., Novartis, ... Conjunct …
Los Angeles, United State, –The report titled Global Conjunctivitis Market is one of the most comprehensive and important additions to QY Research’s archive of market research studies. It offers detailed research and analysis of key aspects of the global Conjunctivitis market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Conjunctivitis market.
Acute Conjunctivitis Treatment Market | Bacterial conjunctivitis | PBIGP
The Future Insights Of Global Acute Conjunctivitis Treatment Market Conjunctivitis, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Conjunctivitis can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but treatment can